SpyGlass Pharma, Inc. Common Stock

NASDAQ: SGP · Healthcare · Biotechnology

PublicHQ Aliso Viejo, CA · OrangeCIK 0001778922Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 68DQ —GM —SS 69

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ filing timeliness, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$39.9M

Employees

as of 2026-08-01

Market cap

$753.3M

as of 2026-08-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$39.9M-$39.9M2025

Operating income-$41.4M-$41.4M2025

Total assets$115.9M$115.9M2025

Liabilities$10.2M$10.2M2025

Equity-$98.8M-$98.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is SpyGlass Pharma, Inc. Common Stock’s financial profile?

SpyGlass Pharma, Inc. Common Stock earned -$39.9M in FY2025 net income.

Peers · Healthcare

Aura Biosciences, Inc.——Climb Bio, Inc.——Bright Minds Biosciences Inc.——BridgeBio Oncology Therapeutics Inc.——Cybin Inc. Common Stock——Jade Biosciences, Inc.——

Neighbors

Orange →

Edwards Lifesciences Corporation$6.1B86A Chipotle Mexican Grill, Inc.$11.9B77B+Rivian Automotive, Inc.$5.4B37D TTM Technologies, Inc.$2.9B73B American Healthcare REIT, Inc.$2.1B56C The Ensign Group, Inc.$5.0B80B+

Key facts

CEOPatrick H. Mooney

SectorHealthcare

IndustryBiotechnology

HeadquartersAliso Viejo, CA

ExchangeNASDAQ: SGP

Employees65

IPO date2008-01-08

Latest filings

8-K2026-08-06 10-Q2026-08-06 10-Q2026-05-14 8-K2026-05-14 8-K2026-03-26 10-K2026-03-26 8-K2026-03-09 8-K2026-02-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.